Cargando…
80例晚期NSCLC吉非替尼治疗长于6个月患者的预后因素分析
BACKGROUND AND OBJECTIVE: Some clinical predictors can be used to evaluate the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer (NSCLC), including female, East-Asian, non-smoker, adenocarcinoma, skin rash, etc. The aim of this s...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000485/ https://www.ncbi.nlm.nih.gov/pubmed/21081047 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.11.10 |
Ejemplares similares
-
吉非替尼治疗32例肺腺癌脑转移的临床经验
Publicado: (2015) -
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
Publicado: (2013) -
厄洛替尼100 mg/天治疗化疗后进展的晚期肺腺癌的临床研究
Publicado: (2011) -
培美曲塞治疗全身化疗和吉非替尼治疗失败的肺腺癌32例临床观察
Publicado: (2010) -
阿法替尼一线治疗5例晚期肺腺癌患者的不良反应分析及相关文献回顾
Publicado: (2014)